Eli Lilly shares rose 4% on Monday, driven by compelling new data for its next-generation obesity dr...
Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market
Eli Lilly shares rose 4% on Monday, driven by compelling new data for its next-generation obesity drug, retatrutide, with analysts and investors expecting...
Author: Reuters
Read Original Article